Thu, Jan 29, 2015, 3:28 PM EST - U.S. Markets close in 32 mins.

Recent

% | $
Quotes you view appear here for quick access.

Hemispherx Biopharma, Inc. Message Board

supersavvyinvestor 9 posts  |  Last Activity: 4 hours ago Member since: Jan 6, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    HEB's "Analysts"

    by deepdeepdeepthroat Jan 9, 2015 12:29 PM
    supersavvyinvestor supersavvyinvestor 4 hours ago Flag

    "the partners at Arrowhead BID expect to receive, or intend to seek, compensation from the company for investment banking services from the Company."

    So, the question is, will Arrowhead BID's investment banking services merely lead to greater dilution?

    Or will this spin around the drain involve death spiral financing with toxic convertibles?

  • Reply to

    Effects of Ampligen on Flumist

    by rainontheparade Jan 18, 2015 4:24 AM
    supersavvyinvestor supersavvyinvestor Jan 22, 2015 9:00 PM Flag

    Once HEB sees the data on how Ampligen compares with placebo, they will bury this study just like the Australia study and the India study.

  • Reply to

    We need the ewan alias !!

    by luc46linda46 Dec 16, 2014 12:31 AM
    supersavvyinvestor supersavvyinvestor Dec 16, 2014 8:09 AM Flag

    You are the one claiming a role for Alferon in treating humans with ebola.

    I frankly am skeptical about whether or not interferons will play a role in treating humans with ebola.

    But, if it does turn out that there is a role, there is no reason based in evidence from human studies to prefer Alferon over recombinant interferons.

  • Reply to

    We need the ewan alias !!

    by luc46linda46 Dec 16, 2014 12:31 AM
    supersavvyinvestor supersavvyinvestor Dec 16, 2014 8:01 AM Flag

    "Thats what this minwit said about ebola....... "

    Oh, please do tell us about the human study that showed Alferon's efficacy for ebola.

  • Reply to

    We need the ewan alias !!

    by luc46linda46 Dec 16, 2014 12:31 AM
    supersavvyinvestor supersavvyinvestor Dec 16, 2014 7:37 AM Flag

    "jonj49307 • 51 minutes ago Flag

    we believe Alferon N Injection could reach peak sales of $130MM in refractory genital warts in the U.S. and over $600MM in refractory HCV alone in Argentina," Wang said"

    And when caught in that deception, jonjon has to dance around and talk about off label indications. lol

    But all of those off label uses can be filled perfectly by recombinant interferon-alpha which is cheap and easy to manufacture. And never forget, there has been only one published human study that compared HEB's brand of expensive interferon-alpha with inexpensive recombinant interferon-alpha, and that study showed absolutely no advantage for Alferon. It was that study that led the company that developed Alferon and got it FDA-approved, ISI, to give up on Alferon and give it away at a fire sale price.

  • Reply to

    We need the ewan alias !!

    by luc46linda46 Dec 16, 2014 12:31 AM
    supersavvyinvestor supersavvyinvestor Dec 16, 2014 7:29 AM Flag

    "The new labeling allows the drug to be used " = the words of shameless liar.

  • Reply to

    We need the ewan alias !!

    by luc46linda46 Dec 16, 2014 12:31 AM
    supersavvyinvestor supersavvyinvestor Dec 16, 2014 7:15 AM Flag

    "The new labeling allows the drug "

    The FDA has not approved any new labeling for Alferon N. End of story.

  • Reply to

    Hey Carter

    by krav_nick Dec 16, 2014 6:52 AM
    supersavvyinvestor supersavvyinvestor Dec 16, 2014 7:04 AM Flag

    HEB does not have the spare cash needed to responsibly pay lavish cash bonuses this year.

  • Reply to

    We need the ewan alias !!

    by luc46linda46 Dec 16, 2014 12:31 AM
    supersavvyinvestor supersavvyinvestor Dec 16, 2014 7:01 AM Flag

    Alferon N was on the market for many years for refractory genital warts in the US, and was a complete flop. Alferon N's peak year for sales was 2007. Here was an FDA analysis of the genital wart therapy market for 2007:

    "Total Prescriptions Market Share
    TOTAL MARKET 1,623,092; 100.0%
    Aldara (imiquimod) 1,194,224; 73.6%
    Carac (flurouracil) 229,905; 14.2%
    Efudex (flurouracil)173,308; 10.7%
    Intron A (interferon alfa-2b) 12,710;0.8%
    Fluoroplex (flurouracil) 12,467; 0.8%
    Alferon N (interferon alfa-n3) 478; 0.0%"

    That's right, in Alferon N BEST EVER year for sales, it sold so poorly, that the FDA rounded its market share to 0.0%.

    Alferon's meager sales never covered the cost of production, and HEB understandably ceased Alferon sales in 2008.

    So, any "analyst" who regurgitates HEB's nonsense predictions about the genital wart market for Alferon N is either mentally #$%$ or a paid stooge.

    I'll let others decide how to describe a pumper who pumps such "analysis" on stock message boards.

HEB
0.2161-0.0039(-1.77%)3:18 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.